RemeGen Co., Ltd. — Capital/Financing Update 2021

Jun 21, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [169 x 52] intentionally omitted <==

RemeGen Co., Ltd. 榮昌生物製藥（煙台）股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9995)

ANNOUNCEMENT ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司 (the “ Company ”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the Company’s announcement dated May 10, 2021 and circular dated May 14, 2021 containing, among other things, related matters of the proposed initial public issue of A Shares (the “ Proposed Issue of A Shares ”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “ Shanghai Stock Exchange ”).

The board (the “ Board ”) of directors (the “ Directors ”) is pleased to announce that the Company has submitted the application materials in respect of the Proposed Issue of A Shares, including the A Share prospectus (the “ A Share Prospectus ”), to the Shanghai Stock Exchange, and has received a letter of acceptance issued by the Shanghai Stock Exchange in respect of the Company’s application for the Proposed Issue of A Shares on June 21, 2021. The A Share Prospectus will be published on the website of the Review and Approval of the Issuance and Listing of Stock on the Science and Technology Innovation Board of the Shanghai Stock Exchange at (kcb.sse.com.cn), and will be published on the website of the Stock Exchange and the website of the Company on the same date pursuant to Rule 13.10B of the Listing Rules.

1

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board RemeGen Co., Ltd. Mr. Wang Weidong Chairman and executive director

Yantai, The People’s Republic of China June 21, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

• For identification purposes only

2